Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events
Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events
复制标题
DOI：
10.1016/j.vaccine.2009.02.106
复制
发表时间：
2009-05-14
期刊：
影响因子：
5.5
通讯作者：
Hviid, Anders
中科院分区：
文献类型：
--
作者：
Callreus, Torbjoern;Svanstroem, Henrik;Hviid, Anders
在疫苗接种计划开始之前和之后确定潜在不良事件的发生率，为评估疫苗安全问题提供了一个有用的框架。丹麦最近开始为少女接种人乳头瘤病毒疫苗(HPV)。使用全国住院登记，我们估计了在接种HPV疫苗前418,289名12-15岁丹麦女孩的免疫介导性疾病的发病率。我们进一步估计了与假设的HPV疫苗接种时间表纯粹是偶然的时间关系中发生的免疫介导疾病的预期病例数量。我们的结果和分析方法为评估青春期女孩接种疫苗后的不良事件报告提供了一个框架。(C)2009爱思唯尔有限公司。保留所有权利。
Determining incidence rates of potential adverse events before and after an immunisation programme is initiated, provides a useful framework for the evaluation of vaccine safety concerns. Human papillomavirus vaccination (HPV) of adolescent girls has recently been introduced in Denmark. Using a nationwide hospitalisation registry we estimated incidence rates of immune-mediated disorders before HPV vaccination in a cohort of 418,289 Danish girls aged 12-15 years. We further estimated the expected number of cases of immune-mediated disorders occurring in temporal relationship to a hypothetical HPV vaccination schedule purely by chance. Our results and analytical approach provides a framework for the evaluation of adverse event reports following immunisation of adolescent girls. (C) 2009 Elsevier Ltd. All rights reserved.